The ITGB1 Knockout 769-P Polyclonal Cells from Ascent Research are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human 769-P renal cell carcinoma line. This product enables loss-of-function studies by disrupting the ITGB1 gene, which encodes the integrin ??1 subunit. The polyclonal nature of this population ensures a heterogeneous knockout profile, reflecting a mixed genetic background that may better recapitulate the complexity of tumor cell populations. The cells are supplied as a viable polyclonal pool, suitable for immediate use in functional assays.
The 769-P host cell line originates from a human clear cell renal cell carcinoma, representing a well-characterized model of cancerous renal epithelial cells. These adherent cells exhibit typical features of renal carcinoma, including aberrant growth factor signaling and altered integrin expression profiles. The 769-P line is widely used in cancer research due to its relevance to kidney tumor biology, providing a clinically pertinent background for investigating integrin-mediated pathways in oncogenesis and metastasis.
ITGB1 encodes the ??1 integrin subunit, which heterodimerizes with various ?? integrins (including ITGA1, ITGA2, ITGA3, ITGA5, and ITGA6) to form receptors for extracellular matrix components such as fibronectin, laminin, and collagen. Upon ligand binding, ??1 integrins cluster and recruit adaptor proteins like talin, vinculin, and paxillin, leading to the activation of focal adhesion kinase (FAK) and Src family kinases. These events propagate downstream signaling through the PI3K-Akt and MAPK (ERK1/2) pathways, modulating Rho GTPases (Rac1, RhoA) to regulate cytoskeletal dynamics, cell proliferation, and apoptosis. Knockout of ITGB1 thus abolishes the principal adhesion and signaling hub, simultaneously impairing multiple intracellular cascades.
In the context of renal cell carcinoma, loss of ??1 integrin function profoundly alters oncogenic phenotypes. The 769-P polyclonal ITGB1 knockout cells provide a critical model to dissect how integrin-mediated adhesion influences tumor cell attachment, spreading, and migration on kidney-relevant ECM substrates. Disruption of ITGB1 signaling can attenuate PI3K-Akt and MAPK pathway activation, potentially reducing survival signals and sensitizing cells to apoptotic cues. This system is particularly valuable for examining crosstalk between integrin signaling and growth factor receptors, such as EGF and TGF-?? pathways, which are often dysregulated in clear cell carcinoma.
These polyclonal knockout cells are suited for a range of experimental applications, including cancer cell adhesion and migration assays, drug target validation for integrin inhibitors, and tumor microenvironment co-culture studies. Representative techniques include western blotting to assess downstream effector phosphorylation, flow cytometry for surface integrin confirmation, quantitative adhesion assays on coated substrates, and Boyden chamber or wound-healing migration/invasion assays. Additionally, cell viability assays under ECM-depleted or chemotherapeutic conditions can uncover dependencies on ??1 integrin signaling. For further technical inquiries, please contact Ascent Research.
